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Mini- Abstract 
This individual participant data meta-analysis assessed the effect of spinal manipulative 
therapy for chronic low back pain. Based on this review, there is no evidence to suggest that 
specific patients characteristics are associated with a clinically better response to SMT as 
compared with other recommended treatments for chronic LBP. 
 
Abstract 
Study design: Individual participant data (IPD) meta-analysis 
Objective. To identify which participant characteristics moderate the effect of spinal 
manipulative therapy (SMT) on pain and functioning in chronic LBP.  
Summary of Background.  The effects of SMT are comparable to other interventions 
recommended in guidelines for chronic low back pain (LBP); however, it is unclear which 
patients are more likely to benefit from SMT compared to other therapies.  
Methods. IPD were requested from randomized controlled trials (RCTs) examining the effect 
of SMT in adults with chronic LBP for pain and function compared to various other therapies 
(stratified by comparison). Potential patient moderators (n=23) were a-priori based on their 
clinical-relevance. We investigated each moderator using a one-stage approach with IPD and 
investigated this interaction with the intervention for each time point (1, 3, 6 and 12 months). 
Results. We received IPD from 21/46 RCTs  (n= 4223)). The majority (12 RCTs, n=2249) 
compared SMT to recommended interventions. The duration of LBP, baseline pain 
(confirmatory), smoking and previous exposure to SMT (exploratory) had a small moderating 
effect across outcomes and follow-up points; these estimates did not represent minimally 
relevant differences in effects; for example, patients with less than one year of LBP 
demonstrated more positive point estimates for SMT vs recommended therapy for the 
outcome pain, (mean differences ranged from 4.97 (95% CI: -3.20 to 13.13) at three months, 
10.76 (1.06 to 20.47) at six months to 5.26 (-2.92 to 13.44) at twelve months in patients with 
over a year LBP. No other moderators demonstrated a consistent pattern across time and 
outcomes. Few moderator analyses were conducted for the other comparisons because of too 
few data. 
Conclusion. We did not identify any moderators that enable clinicians to identify which 
patients are likely to benefit more from SMT compared to other treatments.  
 
Key words: Individual participant data, meta-analysis, spinal manipulative therapy, 
manipulation, low back pain, chronic pain, moderators, randomized clinical trial, subgroup 
analysis, mobilization 
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INTRODUCTION 
Low back pain (LBP) is the world’s leading cause of disability.1 Non-pharmacological 
approaches are the first choice of treatment.2 The treatment options include spinal 
manipulation and mobilization which are used by a variety of heath care providers such as 
osteopaths, chiropractors and physiotherapists. These approaches can be used together or 
alone to treat patients with chronic LBP, and collectively defined as spinal manipulative 
therapy (SMT). 
Many systematic reviews and meta-analyses have found that SMT is an effective treatment 
for patients with chronic LBP with a modest mean effect compared to other interventions.3-8  
Whilst SMT can relieve LBP in some patients, it is not effective for everyone; the number 
needed to treat is in the range of five to ten.9 One potential explanation is that patients with 
‘non-specific’ chronic LBP have different characteristics that influence the intervention 
effect, while another explanation can be the variation in duration, number and type of SMT. 
Relevant subgroups of patients with chronic LBP may exist that might benefit more or less 
from SMT.10 The first step in identifying these subgroups is to examine which participant or 
treatment characteristics moderate the treatment effect  (e.g. age, duration of LBP).10-12   
These moderators are typically not presented in the traditional meta-analyses13 because 
aggregate data on relevant patient characteristics are often not available, are poorly reported, 
or derived and presented differently across studies. More importantly, if the results of 
subgroup analyses are reported, group averages or proportions are presented, which can result 
in ecological bias. The result is patient level intervention-covariate interactions are usually 
not examined or reported, even though they have the potential to better target the 
intervention.14 Whilst some authors have presented appropriate analyses of treatment 
moderation, few trials are large enough to exclude important moderator effects.10 
One way to test interactions of these characteristics with the intervention is to use Individual 
Participant Data (IPD). IPD provides much increased statistical power and allows for 
standardized analyses across studies, using direct derivation of information desired on an 
individual level, independent of whether and how it was reported in original publications. 
Therefore, IPD potentially allows identification of clinical characteristics of patients with 
chronic LBP that may moderate treatment effects.  
 
The specific objective of this IPD meta-analysis is to: 
• Identify individual participant characteristics measured at baseline that moderate the 
effect of SMT for pain and function at one, three, six and twelve months in adults 
with chronic LBP versus 1) recommended interventions; 2) non-recommended 
interventions; 3) sham SMT; 4) SMT + other intervention versus SMT only and 5) 
mobilization versus manipulation.  
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METHODS 
This study was conducted and reported according to the Preferred Reporting Items of 
Systematic Reviews and Meta-Analyses for IPD (PRISMA-IPD) guidelines15 (appendix 
eTable1, http://links.lww.com/BRS/B675). The protocol was registered with PROSPERO 
(https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=25714) and approved 
by the Scientific Review Board of the Vrije Universiteit Amsterdam and by the Ethical 
Committee of the VU University Medical Centre Amsterdam. (Projectnr. 2015.544). 
 A detailed protocol has been published previously.16 The methodology presented in the 
current paper gives an overview of the moderator selection and analysis, while the eligibility 
criteria, search methods for identification of new trials (appendix eTable 11, 
http://links.lww.com/BRS/B675), risk of bias assessment, funnelplots (appendix eFig 1 and 2, 
http://links.lww.com/BRS/B675)collection and extraction of IPD are fully described in the 
published protocol.16 
Types of outcome measures 
Primary outcomes were pain (reported on a 0-10 or 0-100 NRS or VAS scale) and back-
specific function on any scale e.g. Roland Morris Disability Questionnaire, Oswestry 
disability Index. All outcomes were self-reported and converted following decision rules 
(appendix eTable 4, http://links.lww.com/BRS/B675). 
Moderators of treatment effect 
Candidate moderators of treatment response were identified by the research team a-priori 
based on consensus (appendix eTable 5, http://links.lww.com/BRS/B675). In short, the 
selection of patient moderators was based on a specific rationale (e.g. understanding 
behavioral and sociocultural mechanisms by which response is modified or from prognostic 
research (treatment effect modification studies or prognostic factor research))10-12 (see 
protocol16). Of 23 potential moderators identified; six were not analyzed, because data were 
insufficient, unavailable or only available at study level (patient preference/expectancy, 
comorbidities, alcohol use, income, non-specific LBP and for all treatment characteristics). 
The number and frequency of SMT treatments were measured at study level and not at 
patient level in the vast majority of the trials. The same accounts for type of SMT technique 
used. Therefore, contrary to the description in our protocol, we could not analyze moderating 
effects by these types of variables. 
For psychological factors, analyses were only performed for combined depression scales. For 
other psychological scales, there were insufficient data. 
Moderator analyses were classified into confirmatory or exploratory. Moderators in 
confirmatory analyses are those related to specific theory or evidence, while moderators in 
exploratory analyses relate to moderators for which no empirical evidence exists or for which 
a specific theory or mechanism is lacking. Our potential confirmatory moderators were age, 
gender, duration of LBP, psychological factors, treatment preference/expectation and baseline 
pain, function and quality of life. Other moderator analyses were exploratory (appendix 
eTable 5, http://links.lww.com/BRS/B675).17 In both cases, the analytical technique was the 
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same, but for the interpretation of those confirmatory moderators the evidence was 
considered to be stronger.   
Preparing data for moderator analyses 
If data on a variable of interest were not available, we attempted to extract this information 
based on other data in the trial (e.g. information about employment was missing, but there 
was a variable on sick leave). Whenever possible, we used continuous data as presented, 
unless dichotomizing facilitated the translation of findings to clinical practice or was needed 
to meaningfully combine data across trials. The cut-off points were determined by consensus 
of the steering committee (ADZ, MRdB, SMR, MWT and RO)(Appendix eTable 5, 
http://links.lww.com/BRS/B675). For age, we used 65 years as a cut-off point. Additionally, 
duration of LBP was dichotomized into less than one year versus greater than one year. 
Similarly, physical activity was categorized into low (1 or less exercise sessions per week), 
medium (2-3 exercise sessions per week) and high (>3 exercise sessions per week) and 
subsequently dichotomized into low-medium or high. The choice of cut-off for physical 
activity was further evaluated in a sensitivity analysis (low vs medium-high). 
For the outcome pain, all pain scores were converted to a 0-100 points scale following a 
decision rule (appendix eTable 4, http://links.lww.com/BRS/B675). To allow pooling of 
different functional status measures, we recoded the individual scores into Z-scores. for each 
separate time point using pooled standard deviations as nominator. ( 𝑍𝑍 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 =  𝑥𝑥𝑥𝑥−𝑥𝑥̅
𝑆𝑆𝑆𝑆
). 
Analyzing these Z-scores resulted in standardized mean differences (SMD’s). To ease 
interpretation of SMD’s, we converted these to a mean difference (MD) for the 24 point 
Roland Morris Disability Questionnaire, by multiplying the SMD with the population 
standard deviation (SD) of the studies measuring Roland Morris Disability Questionnaire 




𝑥𝑥=0   ni = sample size for each trial; S = standard deviation for each 
trial). 
Data analysis 
We studied moderators of intervention effects when three or more trials within a comparison 
had data on the moderator and the outcome at a specific time point. We used the following 
comparisons: 1) SMT versus recommended interventions including non-pharmacological 
treatment (e.g. exercise) and pharmacological treatment (e.g. NSAIDs, analgesics); 2) SMT 
versus non-recommended interventions (e.g. light massage, diathermy, ultrasound; 3)  sham 
‘placebo’ SMT; 4) SMT + intervention versus intervention alone; 5) high-velocity low-
amplitude SMT versus low-velocity low-amplitude SMT (i.e. manipulation vs. 
mobilization).16 
Potential moderators were analyzed using a one-stage random effect IPD meta-analyses. The 
baseline outcome, treatment, potential moderator and interaction between treatment and 
moderator were included as fixed effects. Study specific intercepts were also included as 
fixed effects. Random treatment and interaction effects were added to the model. (see 
protocol16 and equation 2 in appendix eTable 6, http://links.lww.com/BRS/B675).18 We 
performed these analyses for each time point and each moderator separately to facilitate 
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convergence of models. Centering the patient-level covariates about their study-specific 
means enabled us to separate the within- and across-study interactions.19 The within-study 
interaction explained the patient-level variation in treatment response, while the across-study 
interaction represented the moderator effect on study level. We present the within-study 
interactions. A negative interaction coefficient indicates a more positive or less negative 
estimate of the intervention effect of SMT vs comparison for the index group compared to a / 
the reference group (e.g. females compared to males).  
We refrained from presenting stratified results for subgroups of moderator variables, because 
these include a combination of within- and across-study information because of differences in 
proportions of persons within the separate subgroups between studies. 
Synthesis of evidence 
Assessment of clinical relevance for the main effects analyses was defined as a small, 
medium or large difference and based upon the recommendations of the Cochrane Back and 
Neck group:20 
In a consensus meeting with the project group, we discussed our results to determine whether 
a moderating effect was present. We considered a moderator effect to be present if the 
magnitude of the effect was at least half of our pre-specified clinically relevant main effects; 
i.e., more than 5-points (on a 100-point pain scale) or more than 0.25 for SMD on function 
and there was consistency in the direction of the moderators across three consecutive follow-
up intervals for both pain and function. The arbitrary cut-offs of 5-points or 0.25 SMD were 
used to detect small differences within a moderator as SMT is a low intensity, low cost 
intervention. 
As a crude method to guide interpretation and further synthesize evidence, we combined 
interaction effects with the main treatment effects, in case a moderator fulfilled the criteria 
for described above. Based on this, we assessed whether we could identify a clinically 
relevant treatment effect for potentially relevant moderators (e.g. interaction-effects around 
main effects near zero usually do not imply clinically meaningful effects within subgroups, 
while interaction effect reaching ten points on a 100 point scale does). We assumed that 
subgroup effects based on these interaction effects lie symmetrically around the main effects.  
For example, consider a moderator effect of ‘gender’ of -6 points on a 0-100scale, and a main 
effect of SMT of -8 points. 
This would result in an approximated estimate of main treatment effect for men of -5 points (-
8+3) and for women of 11 points (-8-3). These subgroup effects might indicate minimally 
relevant treatment effect for women, but not for men. 
RESULTS 
Characteristics of trials are presented in (Table 1), Risk of bias criteria and assessment are 
presented in the appendix eTable 2 and 3, http://links.lww.com/BRS/B675. For more details, 
see appendices and protocol.16  
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Identification of trials  
In total, forty-three RCTs met the inclusion criteria, of which 21 (50%) provided data21-41 
(fig.1) from 4223 participants. Baseline characteristics were compared to the published 
results of the individual trials. In two trials, the results differed from the published results: 
one trial provided only data from participants who gave consent to share their data37 while for 
the second trial, all relevant baseline moderator data of the participants were lost.35  
Characteristics of study participants  
Participant characteristics were fairly similar across all comparisons (Table 2 and appendix 
eTable 7, http://links.lww.com/BRS/B675). All trials except one35 provided data on sex and 
age. The average age of the participants was 46.1 (SD 13.78) years, 54.4% were women.  
For employment and BMI, moderator data were missing in 9.6% and 5.9 % of the 
participants respectively, while for all other moderators, data were missing in less than 2% of 
the participants. 
Moderators of SMT for primary outcomes: pain and function  
SMT vs recommended interventions 
For most moderators, no moderating effects were identified except for the moderators 
described below. (Table 3, 4).  
Confirmatory moderator analysis  
For pain and/or function, we found a consistent moderator effect for duration of LBP. 
Patients with less than one year LBP showed more positive/less negative point estimates for 
SMT vs recommended therapy on pain, with MD of 4.97 (95% CI: -3.20 to 13.13) at three 
months, 10.76 (CI: 1.06 to 20.47) at six months and 5.26 (CI -2.92 to 13.44) at twelve 
months; for function: SMD were 0.07 (-0.29; 0.43) at one month, 0.02 (-0.30; 0.34) at three 
months; 0.19 (-0.02; 0.15) at six months to 0.13 (-0.25; 0.52) at twelve months) (Table 3, 4). 
These effects were small, except for pain at 6 months, which showed a moderate effect. 
Converted to a MD for the 24-point Roland Morris Disability Questionnaire, these 
moderating effects amount to 0.35 at one month, 0.10 at three months, 1.06 at six months and 
0.78 at twelve months (Table 3, 4). 
The direction of the main treatment effect of SMT versus recommended interventions for the 
outcome pain was in favor of SMT (e.g. six months: MD -5.56, 95% CI -9.63 to -1.50) (see  
appendix eTable 10, http://links.lww.com/BRS/B675). When adding the moderator effect of 
duration of LBP to the main treatment effect, the results may indicate minimally relevant 
effects, meaning that patients with shorter duration of LBP may benefit from SMT. For those 
with longer duration, SMT has similar benefit compared to recommended interventions. 
For function, patients with pain score over 50 showed more positive/less negative point 
estimates for SMT vs recommended therapy on pain, with SMD of -0.20 (-0.36; -0.04) at one 
month, -0.20 (-0.37; -0.03) at three months, -0.22 (-0.39; -0.06) at six months and -0.14 (-
0.33; 0.04) at twelve months. These effects were small. 
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Exploratory moderator analysis 
For pain and/or function, we found a consistent moderator effect for smoking. Non-smokers 
showed more positive/less negative point estimates for SMT vs recommended therapy on 
pain, with MD of 3.19 (-3.20; 9.58) at one month, 2.45 (-3.68; 8.58) at three months, 6.02 
(0.12; 11.92) at six months to 4.85 (-1.33; 11.03) at twelve months; for function: SMD were 
0.24 (0.00; 0.48) at one month, 0.22 (-0.02; 0.47) at three months; 0.14 (-0.11; 0.38) at six 
months to 0.29 (0.02; 0.56) at twelve months) (see for conversion to the 24-point Roland 
Morris Disability Questionnaire Table 3, 4). These effects were small. 
For pain and/or function, we found a consistent moderator effect for previous SMT for LBP. 
Patients that had no previous SMT showed more positive/less negative point estimates for 
SMT vs recommended therapy on pain, with MD of -3.97 (-13.12; 5.19) at one month, 5.34 (-
3.25; 13.95) at three months, 6.86 (-1.63; 15.35) at six months to 15.59 (6.18; 24.99) at 
twelve months; for function SMD were -0.11 (-0.49; 0.26) at one month, -0.07 (-0.46; 0.32) 
at three months; 0.14 (-0.20; 0.49) at six months to 0.52 (0.09; 0.84) at twelve months) (Table 
3, 4). This effect (i.e. patients that had no previous SMT improved more than patients that 
had previous SMT for the outcomes pain and function with SMT compared to other 
recommended treatments) was small, except for pain and functional status at twelve months, 
which showed a moderate effect. (Table 3, 4).  
SMT vs non-recommended interventions, SMT as adjuvant therapy and Manipulation vs 
Mobilization 
Ninety percent of the moderator analyses for these comparisons were not performed due to 
too few data. In the analyses performed (mainly age, sex and BMI), we found no consistent 
effect for any moderator. (Appendix eTables 8-9, http://links.lww.com/BRS/B675)  
DISCUSSION 
This study is the first large-scale IPD meta-analysis which attempted to identify potential 
moderators for those undergoing SMT for chronic LBP.  In short ,the results suggest no 
substantive moderation in the effect of SMT compared to other interventions. We did, 
however identify (possible) small moderation effects for the following confirmatory 
moderators: duration of LBP and greater pain at baseline, and for the exploratory moderators 
smoking and previous exposure to SMT. However these effects were too small to be 
clinically-relevant. This suggests that targeting SMT, based upon individual characteristics 
examined in this study is not warranted at this time.   
Analyses of moderator effects of SMT have rarely been performed and have largely been 
restricted to aggregate meta-analytic approaches, These different approaches make it difficult 
to compare those results to ours. Results from an earlier systematic review10 indicated 
moderating effects of psychosocial and belief factors, expectations and baseline pain and 
disability.  
Two earlier IPD studies evaluated moderators for other types of treatment for LBP and 
identified small effects for the following moderators: age, gender, BMI, no heavy physical 
demands, psychosocial factors, back pain disability, pain severity and medication use.42 43 
However, our analyses suggest only a weak moderating effect of  baseline pain for functional 
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status in our confirmatory analysis. There are a number of reasons why the results of our 
moderator analyses might differ from the other studies.10 43-45 Most importantly, these earlier 
studies examined various types of conservative treatments for LBP (e.g. cognitive behavioral 
therapy) and the comparisons were chosen differently than in our study. 
An important difference of our IPD analysis compared to traditional aggregate meta-analyses 
is that we could adjust for covariates and were not dependent upon how these data were 
reported in the study publications. IPD allowed investigation for moderators in a more 
sophisticated and valid way. In the IPD analysis one can separate the between-study and the 
within-study interaction. The between-study interaction describes the moderation effects at 
study level. This is what is analyzed in a meta-regression or subgroup analyses in traditional 
aggregate meta-analysis. Results of these analyses can be severely affected by ecological 
biases.19 The real interest lies in the within-study interaction, which describes the effects of 
covariates on the treatment effectiveness at the patient level.  
Strengths and limitations: The most important strength is our large data set (i.e. 21 RCTs) 
from various countries resulting in a dataset which included many different moderators and 
thousands of patients of which over 2000 were in the SMT vs recommended intervention 
comparison. Most moderator analyses in this comparison included more than 500 patients 
provided from at least three trials. It has been suggested that this might be robust.10 Far fewer 
patients were included in the moderator analyses for the other comparisons. Therefore, our 
(exploratory) moderator results should serve as a guide for future research only.  
We collected a wide variety of moderators, but many moderators were measured differently 
across trials or were not measured at all. For example: duration of LBP was measured as a 
continuous variable in some trials and as a categorical variable. Only age, sex and BMI were 
measured similarly. This meant that in many instances we had to compromise our best 
detailed measures by categorizing the data, which led to loss of information. Importantly, 
there was a large diversity in frequency (1 to 6 times a week), duration (2 to 12 weeks) and 
number of treatments (2 to 36 (average of 8)) in included trials and these characteristics were 
measured at study-level in most trials. Therefore, the moderator analyses with treatment 
characteristics were not possible in contrast to what we planned in our protocol. A better 
understanding of the etiology of chronic LBP and key mechanisms involved in the effects of 
SMT would help to identify moderators.  
We did not assess the effects of imputing missing data on outcomes and moderators. 
Methodology for imputing missing values in IPD meta-analysis is still in the developmental 
phase.46 47 To our knowledge standard imputation methods for IPD meta-analysis of 
moderator effects have not been described in the literature. These models are especially 
challenging as they should result in valid estimates for the one-stage models we used that 
distinguish within-study and between-study interaction effects. 
Additionally, we did not investigate multiple moderators in the same analysis as no evident 
clinically important moderators were found, although others43 looked at multiple moderator at 
a lower level of statistical significance. At this moment our study clearly presents exploratory 
results to inform future studies.   
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Another challenge we encountered is the definition of clinical-relevance of the treatment 
moderator effects. For main effects, three-levels of clinical relevance (small, medium and 
large) are broadly used across systematic reviews, and are recommended by the Cochrane 
Back and Neck Review Group.20 48 However, for moderator analysis, we think clinical 
relevance should not be defined by the same criteria as for the main treatment effects. 
Importantly, we interpreted the moderator effects considering hypothesized mechanisms and 
consistency of results across time and outcome measures. In summary, we used a consensus 
approach for the arbitrary cut-off points for drawing our conclusions to detect small 
difference within a moderator for low intensity, low cost intervention comparisons. This is 
subjective, but in our view the best method currently available.  
Another potential limitation is selection bias. We included only 50% of the eligible trials, 
whch is comparable to other IPD studies.49 50 However, the effect sizes, methodological 
quality and range of publication dates of studies where IPD was collected was comparable 
with the studies where no IPD was present. We also missed the data of the most recent trials 
as we only included trials until 2016, because collection of data for an IPD is time consuming 
as also seen in other IPD studies.42 It took four years to collect and analyze the data, which is 
comparable to IPD meta-analyses in other fields.43 51 When we updated our search May 4th, 
2018, we found that the most recent trials were small in size, had few data on patient 
characteristics and were considered to have a high risk of bias.52-56 Therefore, it is not likely 
that these most recent trials or the studies where IPD was not provided, would materially 
change our results.  
The clinical implication of this IPD study is that based on the evidence to date there is no 
justification for using specific patient characteristics to target SMT for chronic LBP patients.  
In addition to more detailed study of the etiology of chronic LBP and mechanism(s) of SMT, 
future initiatives should focus on standardizing the manner in which inclusion and exclusion 
criteria, outcomes and moderators are measured and reported.54 57-59 This will facilitate an 
effective comparison of interventions across trials. Additionally, our wish is to form an 
international IPD repository of RCTs which have examined the effect of conservative 
treatment for LBP. This will provide an excellent resource for researchers with advantages 
such as the potential for future network meta-analysis and to standardize, safeguard and store 
data centrally. To facilitate this, we encourage researchers in future grant applications to 
obtain permission to share their data and to include costs of uploading their final data into a 
repository as well as permission from Research Ethical Committees and participants for 
sharieng these data. However three large IPD meta-analyses of non-pharmacological 
treatments for low back pain have failed to find any consistent and clinically important 
moderation effects indicates that this line of research is very unlikely to generate important 
finding to improve patient care.   
CONCLUSION 
Based on the current IPD analyses, there is no evidence for moderating effects of specific patient 
characteristics that enable clinicians to identify which patients are likely to benefit more from 
SMT compared to other treatments. Future research dealing with the effectiveness of SMT would 
benefit from shared procedures for including important treatment effect modifiers. 
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ABBREVIATIONS 
IPD: individual participant data 
LBP: low back pain 
MD: mean difference 
PRISMA-P: Preferred Reporting Items of Systematic Reviews and Meta-Analyses Protocol  
RCT: randomized clinical trial 
RR: relative risk 
SD: standard Deviation 
SMD: standard mean difference 
SMT: spinal manipulative therapy 
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• The effects of SMT are comparable to other interventions recommended in guidelines 
for chronic low back pain (LBP); however, it is unclear which patients are more likely 
to benefit from SMT compared to other therapies.  
 
• Based on this review, there is no evidence to suggest that specific patients or 
treatment characteristics are associated with clinically better response to SMT as 
compared to other (recommended) treatments for chronic low back pain.  
 
• This may well be a result of the great variation in reporting of potential treatment 
modifiers. 
 
• Future initiatives should also focus on standardizing the manner in which inclusion 
and exclusion criteria, outcomes and moderators are defined, measured and reported.  
 
• This will facilitate an effective comparison of interventions across trials. 
•  
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Figure 1 Flow diagram of study inclusion 
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Table 1 Descriptives of studies evaluating the effects of SMT on outcomes included in the 


















Max no. treatments 






42 1. Spinal manipulation Therapy  
plus active exercise  (n = 22) 
2. Detuned ultrasound plus 












8 over 4-8 weeks 
Bronfort 
(2011) 
USA 301 1. Supervised exercise (n= 101) 
2. Spinal manipulative therapy 
(n=100) 










discharged from care 
if the treating 
clinician felt that 
maximum clinical 
benefit was 




USA 192 1. Spinal manipulative therapy 
plus home exercise and advice 
(n=96) 















Italy 210 1. Back school (n=70); 2. 
Individualized physiotherapy 
(n=70); 3. Spinal manipulative 
therapy (n=70) 






4-6 sessions per 
week for 4-6 wks 
Cook 
(2013) 
USA 154 1. Thrust manipulation(n=77) 

















1st 2 visit only 
afterwards clinician 
was allowed to 
choose technique 
they felt most 




Australia 240 1. General  exercise (n=80)  
2. Motor control exercise 
3. Spinal manipulative therapy 
> 3 mo Physical 
therapist 






12 over 8 wks 
Gudavell
i (2006) 
USA 235 1. Flexion distraction 
mobilization (n=123) 
2. Exercise therapy (n=112) 
> 3 mo Chiropra







16 over 4 wks 
Haas USA 400 1. 0 SMT (spinal manipulative 
therapy) + 18 LM (light 




18 over 6 wks 
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(2014) massage) (n=100) 
2. 6 SMT + 12 LM (n=100) 
3. 12 SMT + 6 LM (n=100) 






Belgium 32 1. Spinal manipulative therapy 
(n=16) 










1 over 2 wks 
Hondras 
(2009) 
USA 240 1. High-velocity low-amplitude 
Spinal manipulative therapy (n 
= 96) 
2. Low-velocity variable 
amplitude spinal mobilization 
(n = 95) 
3. Medical care (n=49) 
> 4 wks Chiropra














12 over 6 wks 
Hsieh 
(2002) 
USA 206 1. Back school (n = 48) 2. 
Myofascial therapy (n = 51)  
3. Joint manipulation (n = 49) 
4. Combination of treatments 2 
& 3 (n = 52) 
> 3 wks 
to  
< 6 mo 
Chiropra




9 over 3 wks 
Petersen 
(2011) 
Denmark 350 1. McKenzie therapy (n=175) 
2. Spinal manipulative therapy 
(n=175) 











Sweden 47 1. Stabilizing training group (n 
= 24) 
2. Manual therapy group (n = 
23) 
> 6 wks Manual 
therapist 
(n = ?) 
MOB 6 over 6 wks 
Skillgate 
(2007) 
Sweden 409 1. Naprapathy (n = 206) 
2. Standard care or "evidence-
based" care (provided by 
physician) (n = 203) 
> 2 wks Naprapat












1. Best care in general practice 
(n = 338) 
2. Best care plus exercise alone 
(n = 310) 
3. Best care plus private 
manipulation alone (n = 180) 
4. Best care plus NHS 
manipulation alone (n = 173)  
5. Best care plus private 















8 over 12 wks 
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172) 
6. Best care plus NHS 




India 30 1. Exercise (n=15) 
2. Lumbar mobilisation and 
exercise (n=15) 





8 over 4 wks 
Vismara 
(2012) 
Italy 21 1. Osteopathic manipulation 
and Specific exercise (n=10) 
 2. Specific exercise (n=11) 






10 over 10 wks? 
Walker 
(2013) 
Australia 183 1. Sham group (n=91); 2. Usual 








2 over 2 wks 
Wilkey 
(2008) 
UK 63 1) Hospital pain clinic (n = 33) 
2) Chiropractic treatment (n = 
30)* 
>3 mo  Chiropra




16 over 8 wks 
Xia 
(2015) 
USA 192 1. Thrust spinal manipulation 
(n=72) 
2. Non thrust spinal 
manipulation (n=72) 
3. Control (n=48) 







4 over 2 weeks 
Zaproudi
na (2009) 
Finland 73 1. Traditional bone setting  (n = 
36) 
2. Physical therapy  (n = 37)** 





5 over 10 wks 
 wks = weeks; mo = months; ? = unclear/unknown 
*More patients data provided than published  
** Only patient data used if patient consented to be included in our database, therefore less 
patients than published  
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Table 2: Patient characteristics at baseline for groups receiving SMT vs groups receiving 
recommended interventions 
 SMT vs recommended 
interventions 
(m= 12; n=2475 ) 
 
Demographic data SMT Recommended 
interventions 
Age, mean (SD) years(m=11, n=2409)  47.13 (13.63) 47.18 (13.99) 
Sex, n (%) female (m=11, n=2412) 667 (56.9) 684 (55.2) 
BMI, mean (SD) (m=8, n=1434) 26.85 (5.12) 26.79 (5.10) 
Ethnicity, n (%) white (m= 5, n=861) 409 (90.9) 388 (88.1) 
Lifestyle factors   
Physical activity, n (%) (m= 6, n=824)   
Low (1 or less than once a week)  115 (31.9) 166 (35.9) 
Medium (2-3x a week)  146 (40.4) 166 (35.9) 
High (more than 3x a week)  100 (27.7) 131 (28.3) 
Smoker, n (% non-smokers) 
(m=6, n=1173) 
451 (79.5) 453 (74.8) 
Alcohol use (%) * * 
Socio-demographics   
Marital Status, n (%) married; living with a partner (m= 6, n=1173) 397 (69.0) 404 (67.6) 
Level of Education, n (%) low/ middle (m= 7, n= 1672) 600 (68.0) 534 (67.6) 
Income, n (%) * * 
Employment status, n (%) at work (m= 9, n= 2126) 818 (77.9) 770 (71.6) 
Nature and severity of LBP   
Duration of LBP, n (%)  less than 12 months (m=7, n=1252) 121 (20.3) 149 (22.9) 
Leg pain, n (%) (m= 5, n=1038) 320 (59.0) 281 (56.7) 
Previous LBP treatment received, n (%) (m=5, n=930) 258 (27.7) 218 (23.4) 
Previous physiotherapy for low back pain received, n (%) (m=5, n=771) 64 (8.3) 72 (9.3) 
Previous SMT for low back pain received, n (%) (m=6, n=988) 209 (21.2) 111 (11.2) 
Used medication for low back, n (%) (m=6, n=1018) 200 (19.6) 269 (26.4) 
Non-specific, n (%) * * 
Comorbidities * * 
Type of treatment * * 
Psychological factors SMT Control 
Depression, n (%) (m= 5, n=1297) 43 (6.2) 75 (12.5) 
Treatment preference/expectations * * 
Primary outcomes   
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Pain SMT Recommended 
interventions 
Combined pain score at baseline, mean (SD), (m=12, n=2441)  49.47 (22.27) 49.75 (21.59) 
Combined pain score at one month, mean (SD), (m=10, n=1948)  34.19 (22.95) 35.81 (23.91) 
Combined pain score at three months, mean (SD), (m=9, n=1673)  27.92 (23.03) 32.12 (24.25) 
Combined pain score at six months, mean (SD), (m=8, n=1321)  27.35 (23.12)  32.31 (23.90) 
Combined pain score at 12 months, mean (SD), (m=10, n=1816)  31.80 (25.81) 33.32 (25.38) 
Function   
RMDQ sum score at baseline, mean (SD), (m=9, n=2174)  8.99 (4.96) 10.07 (5.44) 
RMDQ sum score at one month, mean (SD), (m=8, n=1760)  5.62 (5.02) 6.65 (5.37) 
RMDQ sum score at three months,  mean (SD), (m=8, n=1648)  4.81 (5.14) 5.52 (5.34) 
RMDQ sum score at six months, mean (SD), (m=8, n=1348) 4.99 (5.44) 6.26 (5.95) 
RMDQ sum score at 12 months, mean (SD), (m=7, n=1575) 5.44 (5.67) 6.16 (5.92) 
Secondary outcomes   
SF36 Physical Component Scale of SF36 at baseline, mean (SD), (m=5, n= 
1362) 
40.69 (7.15) 41.06 (7.59) 
SF36 Mental Component Scale of SF36 at baseline, mean (SD), (m=5, n= 
1362) 
43.83 (9.05) 45.08 (9.60) 
Medication use at baseline, 
n (% medication use)  
(m =3, n= 668) 
145 (21.7) 216 (32.3) 
SD= standard deviation; m = number of studies; n = number of participants; * less than 3 
studies or combining categories was not meaningful 
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Table 3: Moderator effects of SMT vs recommended interventions for pain. Within-study 
interaction (• ) and 95% confidence intervals (CI) with the intervention effects of random-
effect models adjusted for baseline using REML separating, between-study and within-study 
variation are presented.  
Combined Pain scale Follow-up 
1 month 








•  (95% CI)  
m; n  
 
12 months 
•  (95% CI)  
m; n 
Demographic moderators     
Sex: 
(reference:  male) 
-1.63 (-5.02; 1.75)  
9; 1859 
-2.76 (-6.81; 1.28)  
8; 1592 
-5.11 (-9.69; -0.54)  
7; 1270 
-6.69 (-10.71; -2.67)  
9; 1740 
Age *: 
(reference:  <65 years old) 
-1.74 (-6.03; 2.55) 
9; 1859 
-0.56 (-7.96; 6.84)  
8; 1590 
-9.42 (-17.65; -1.20)  
7; 1268 
2.60 (-5.27;10.47)  
6; 1042 
Body mass index: 
(reference:  <30) 
-1.96 (-7.30; 3.38)  
6; 1060 
3.78 (-3.10; 10.65)  
5; 924 
4.36 (-2.28; 11.00)  
6; 1056 




(reference: other than white)  
-1.96 (-10.08; 6.15)   4; 699                                                                                                                                                                                                                                                                                                                                                         
 
5.12 (-7.37; 17.60)
3; 492                                                                                                                                                                                                                                                                                                                       
 
-0.08 (-13.39; 13.22) 3; 
465                                                                                                                                                                                                                                                                                                                                                                                                                               
 
2.77 (-9.48; 15.02)
3; 469                                                                                                                                                                                                                               
 
Lifestyle factors     
Physical activity: 
(reference: 3 or less a week) 
(reference: 1 or less a week) 
-0.46 (-7.45; 6.54)  
4; 533                                                                                                                                                                                                                                                                                                                                                                                                                                      
 
-3.96 (-10.07; 2.16)  
4; 533                                                                                                                                                                                                                                                                                                                                                                                                                                           
-4.84 (-11.59; 1.92)  
7; 721                                                                                                                                                                                                                                                                                                                                                                                                                                              
 
-2.06 (-8.31; 4.18)  
7; 721                                                                                                                                                                                                                                                                                                                                                                                                                                             
-4.67 (-11.47; 2.14)  
4; 681                                            
 
1.00 (-5.89; 7.60) 
4; 681                                                  
-0.02 (-7.58; 7.54)  
5; 661                                                    
 
-3.22 (-10.35; 3.90)  
5; 661                                                    
Smoker: smoker 
(reference:  non-smoker)   
3.19 (-3.20; 9.58)  
5; 886 
2.45 (-3.68; 8.58)  
4; 866 
6.02 (0.12; 11.92)  
5; 891 
4.85 (-1.33; 11.03)  
4; 806 
Alcohol use ‡ ‡ ‡ ‡ 
Socio-demographics     
Marital Status: (reference: not 
involved in relation) 
2.60 (-3.11; 8.31)  
6; 1076 
1.39 (-4.47; 7.35)  
4; 802 
 
1.84 (-4.19; 7.87)  
5; 834 
 
-0.28 (-6.11; 5.57)  
4; 764  
Employment status:  
(reference: not employed) 
5.69 (0.32; 11.06)  
7; 1622 
0.88 (-5.72; 7.49)  
7; 1440 
5.12 (-2.94; 13.19)  
6; 1191 
0.96 (-4.93; 6.86)  
8; 1572 
Level of Education: (reference: 
low or middle)   
-0.42 (-4.62; 3.77)  
6; 1377 
-1.52 (-7.51; 4.48)  
5; 1117 
-3.31 (-14.50; 7.88)  
4; 625 
-2.54 (-9.27; 4.19)  
5; 1066 
Income  ‡ ‡ ‡ ‡ 
Nature and severity of LBP     
Duration of LBP *:  
(reference: < 1 year)  
-1.69 (-10.37; 7.00)  
5; 876 
4.97 (-3.20; 13.13)  
4; 700 
10.76 (1.06; 20.47)  
5; 875 
5.26 (-2.92; 13.44)  
5; 854 
Radiation:  
(reference:  no leg pain)  
-4.13 (-9.68; 1.43)  
3; 649 
 
-2.56 (-9.18; 4.06)  
4;  716 
 
0.43 (-6.56; 7.41)  
3;  636 
 
-4.41 (-11.33; 2.52)  
4;  682 
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Previous LBP treatment 
received:  
(reference: no) 
0.23 (-5.06; 5.53)  
5; 878 
2.42 (-9.09; 4.25)  
4; 675 
-0.36 (-7.18; 6.45)  
3; 626 
-0.95 (-8.15; 6.25)  
3; 622 
Previous Physio for LBP:  
(reference: no)  
-10.83 (-19.42; -2.25)  
3; 448 
-3.38 (-11.51; 4.74)  
4; 679 
2.41 (-6.64; 11.46)  
4; 639 
-1.55 (-10.13; 7.02)  
4; 624 
Previous SMT for LBP:  
(reference: no) 
-3.97 (-13.12; 5.19)  
4; 629 
5.34 (-3.25; 13.95)  
4; 676  
6.86 (-1.63; 15.35)  
4; 636 
15.59 (6.18; 24.99)  
4; 621 
Previous medication for LBP:  
(reference: no) 
1.32 (-3.47; 6.13)  
5; 887 
-2.99 (-8.44; 2.46)  
6; 902 
-2.43 (-8.22; 3.37)  
4; 790 
-1.69 (-11.33; 7.96)  
6; 862 
Comorbidities ‡ ‡ ‡ ‡ 
Psychological factors     
Depression *:  
(reference: no depression) 
1.45 (-6.78; 9.68)  
4; 1053 
 
-1.06 (-11.23; 9.11)  
4; 860 
 




‡ ‡ ‡ ‡ 
Primary/secondary outcomes at 
baseline as moderator 
    
Baseline pain score 
per 10 points change * 
-0.20 (-1.2; 0.80)  
10; 1922) 
-0.70 (-2.10; 0.80)  
9; 1922) 
-0.40 (-0.18; 1.10)  
8; 1922) 
-1.1 (-2.90; 0.70)  
9; 1791) 
Baseline function scales 
combined  (z-score) * 
-1.25 (-3.90; 1.39)  
10; 1914 
 
-0.77 (-3.43; 1.87)  
9; 1641 
 
-1.73 (-4.27; 0.82)  
8; 1313 
 
-0.90 (-4.07; 2.26)  
10; 1783 
 
MCS -0.09 (-0.40; 0.21)  
5; 1190 
-0.01 (-0.28; 0.26)  
4; 1121 
0.17 (-0.16; 0.49)  
4; 681 
-0.19 (-0.48; 0.11)  
4; 1046 
PCS 0.19 (-0.36; 0.73)  
5; 1190 
-0.07 (-0.52; 0.38)  
4; 1121 
-0.40 (-1.07; 0.28) 
4; 681 
0.09 (-0.50; 0.69)  
4; 1046 
A negative interaction coefficient indicates a more positive / less negative effect of SMT 
versus recommended therapies for the index group (e.g. females)  as compared to the 
reference group (e.g. males). 
•  (95% CI) = within-study interaction and confidence interval: the mean difference in pain 
score for the specific moderator for SMT vs recommended therapies on scale from 0-100; 
m=number of studies; n= number of participants 
* confirmatory moderator analysis 
‡ not enough data 
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Table 4 Moderator effects of SMT vs recommended interventions for function. Within-study 
interaction (• ) and 95% confidence intervals (CI) with the intervention effects of random-
effect models adjusted for baseline using REML, separating between-study and within-study 
variation are presented. 
Standardized mean 












•  (95% CI)  
m; n  
 
12 months 
•  (95% CI)  
m; n 
Demographic moderators     
Sex: 
(reference:  male) 
-0.03 (-0.16; 0.10)  
 9; 1876 
0.06 (-0.09; 0.21)    
10; 1837 
0.01 (-0.15; 0.18)  
8; 1439 
-0.02 (-0.17; 0.14) 
9; 1775 
Age *: 
(reference:  <65 years old) 
-0.03 (-0.17; 0.12)   
9; 1876 
-0.06 (-0.25; 0.13)    
10;  1835 
-0.23 (-0.45; -0.01)  
8; 1437 
-0.32 (-0.57; -0.07)  
9; 1773 
Body mass index:  
(reference:  <30) 
-0.07 (-0.26; 0.12)  
6; 1047 
-0.18 (-0.42; 0.07)  
7; 1139 
-0.06 (-0.30; 0.17)  
7; 1225 
0.15 (-0.14; 0.44)  
6; 1055 
Ethnicity: white vs other 
(reference: other than white)  
-0.19 (-0.55; 0.17)  
4; 691 
0.07 (-0.39; 0.53)  
5; 707 
-0.23 (-0.65; 0.19)  
4; 630 
0.03 (-0.38; 0.44)  
3; 469 
Lifestyle factors     
Physical activity: 
(reference: 3 or less a week) 
(reference: 1 or less a week) 
 
-0.002 (-0.008; 0.002)  
4; 511 
-0.11 (-0.33; 0.11)  
4; 511 
 
-0.002 (-0.009; 0.004)  
6; 739 
-0.05 (-0.27; 0.18)  
6; 739 
 
-0.13 (-0.40; 0.14)  
4; 659 
-0.13 (-0.34; 0.09)  
4; 659 
 
0.00 (-0.01; 0.01)  
5; 676 
-0.10 (-0.33; 0.14)  
5; 676 
Smoker: smoker 
(reference: non-smoker)   
0.24 (0.00; 0.48)  
5; 873 
0.22 (-0.02; 0.47)  
6; 1075 
0.14 (-0.11; 0.38)  
6; 1050 
0.29 (0.02; 0.56)  
4; 801 
DZ converted to a MD on 
the 24 point RMDQ scale 
1.08 1.11 0.72 1.54 
Alcohol use ‡ ‡ ‡ ‡ 
Socio-demographics     
Marital Status: 
(reference: not involved in 
relation) 
-0.12 (-0.29; 0.05)  
6; 1066 
 
-0.09 (-0.29; 0.12)  
 6; 1016 
 
-0.08 (-0.26; 0.10)  
6; 1005 
 
-0.12 (-0.33; 0.10)  
 4; 777 
 
Employment status:  
 (reference: not employed) 
0.10 (-0.08; 0.27)  
7; 1657 
-0.17 (-0.39; 0.04)  
 8; 1665 
0.06 (-0.16; 0.27)  
7; 1377 
 
-0.06 (-0.36; 0.23)  
8; 1606 
 
Level of Education:  
(reference: low or middle)   
-0.17 (-0.37; 0.01)  
6; 1398 
-0.11 (-0.29; 0.08)  
7; 1363 
-0.07 (-0.27; 0.13)  
5; 796 
-0.14 (-0.35; 0.05)  
5; 1106 
Income  ‡ ‡ ‡ ‡ 
Nature and severity of LBP     
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Duration of LBP *: >1 year 
(reference: < 1 year)  
0.07 (-0.29; 0.43)  
5; 861 
0.02 (-0.30; 0.34)  
6; 910 
0.19 (-0.02; 0.39)  
6; 1031 
0.13 (-0.25; 0.52)  
5; 848 
DZ converted to a MD on 
the 24 point RMDQ scale 
0.35 0.10 1.06 0.78 
Radiation: leg pain 
(reference:  no leg pain)  
-0.16 (-0.40; 0.80)  
3; 660 
0.04 (-0.18; 0.27)  
5; 911 
-0.01 (-0.22; 0.21)  
4; 820 
-0.08 (-0.33; 0.17)  
4; 681 
Previous LBP treatment 
received: (reference: no) 
0.09 (-0.11; 0.29)  
5; 884 
0.11 (-0.12; 0.34)  
5; 871 
0.02 (-0.21; 0.15)  
5; 812 
0.12 (-0.14; 0.39)  
4; 637 
Previous Physio for LBP:  
(reference: no)  
-0.08 (-0.63; 0.48)  
3; 426 
0.04 (-0.33; 0.40)  
5; 696 
0.18 (-0.19; 0.56)  
4; 615 
0.11(-0.27; 0.50)  
4; 634 
Previous SMT for LBP:  
(reference: no) 
-0.11 (-0.49; 0.26)  
4; 616 
-0.07 (-0.46; 0.32)  
6; 885 
0.14 (-0.20; 0.49)  
5; 795 
0.52 (0.09; 0.95)  
4; 631 
DZ converted to a MD on 
the 24 point RMDQ scale 
-0.49 -0.36 0.74 2.93 
Previous medication for 
LBP: (reference: no) 
-0.02 (-0.22; 0.19) 
5; 887 
-0.11 (-0.33; 0.09) 
6; 903 
-0.20 (-0.41; 0.004)  
4; 790 
-0.11 (-0.39; 0.17)  
6; 877  
Comorbidities ‡ ‡ ‡  
Psychological factors     
Depression *:  
(reference: no depression) 
0.28 (-0.03; 0.58)  
4; 1075 
0.33 (-0.02; 0.69)  
5; 1066 
0.13 (-0.26; 0.51)  
3; 505 




‡ ‡ ‡ ‡ 
Primary/secondary 
outcomes at baseline as 
moderator 
    
Baseline function scales 
combined  (z-score 
-0.04 (-0.17; 0.09)  
10; 1939 
+0.01 (-0.10; 0.13)  
11; 1892 
-0.04 (-0.17; 0.08)  
9; 1490 
-0.05 (-0.17; 0.07)  
10; 18266 
Baseline pain dichotomized 
*:  (reference: baseline 
painless than 50) 
-0.20 (-0.36; -0.04)  
10; 1932 
-0.20 (-0.37; -0.03)  
11; 1882 
-0.22 (-0.39; -0.06)  
9; 1506 
-0.14 (0.33; 0.04)  
10; 1806 
 -0.90 -0.92 -1.00 -0.64 
MCS 
per 10 points change  
-0.00 (-0.10; 0.10)  
5; 1204 
-0.03 (-0.16; 0.08)  
6; 1358 
0.09 (-0.07; 0.25 ) 
5; 864 
0.00 (-0.12; 0.12)  
4; 1069 
PCS 
per 10 points change 
0.03 (-0.17; 0.23)  
5; 1204 
-0.06 (-0.18; 0.06)  
6; 1358 
-0. 13 (-0.32; 0.07 ) 
5; 864 
0.00 (-0.22; 0.21)  
4; 1069 
A negative interaction coefficient indicates a more positive / less negative effect of SMT versus recommended therapies for 
the index group (e.g. females)  as compared to the reference group (e.g. males). 
•  (95% CI) = within-study interaction and confidence interval of the interaction term: the difference in Z score for the 
specific moderator for function for SMT vs recommended therapies; m=number of studies; n= number of participants 
* confirmatory moderator analysis 
‡ not enough data 
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